Request Demo

Last update 30 Jun 2026

Gabapentin

Last update 30 Jun 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryGabapentin is a small molecule drug developed by Pfizer that functions as a CACNA2D2 and Cav2.2 blocker. The drug has been approved for the treatment of various conditions, including anxiety, cough, diabetic neuropathies, epilepsy, fibromyalgia, restless legs syndrome, and seizures. Gabapentin's mechanism of action involves blocking the influx of calcium ions into neurons, thereby reducing their excitability and relieving symptoms such as pain and convulsions. Since its initial approval in 1993, Gabapentin has become a widely prescribed medication for the treatment of these conditions. However, it is important to note that Gabapentin may cause certain side effects, such as drowsiness, dizziness, and difficulty with coordination. Therefore, its use must be closely monitored by healthcare providers, and patients should follow the prescribed dosage and usage guidelines.

Drug Type

Small molecule drug

Synonyms

1-(Aminomethyl)cyclohexaneacetic acid, Gabapentin (JAN/USP/INN), CI-945

+ [17]

Target

CACNA2D1 x CACNA2D2

Action

blockers

Mechanism

CACNA2D1 blockers(Voltage-gated calcium channel alpha2/delta subunit 1 blockers), CACNA2D2 blockers(Voltage-gated calcium channel alpha2/delta subunit 2 blockers)

Therapeutic Areas

Immune System DiseasesNervous System DiseasesEndocrinology and Metabolic Disease+ [3]

Active Indication

Peripheral neuralgiaNeuralgia, PostherpeticAnxiety Disorders+ [8]

Inactive Indication

Amyotrophic Lateral SclerosisCarpal Tunnel SyndromeDyspepsia+ [7]

Originator Organization

Pfizer Inc.

Active Organization

Viatris Pharma GmbHParke Davis (India) Ltd.

Pfizer Inc.

+ [4]

Inactive Organization

Viatris, Inc.

Assertio Therapeutics, Inc.Hunter New England Area Health Service

+ [1]

License Organization

Fuji Pharma Co., Ltd.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Lotus Pharmaceutical Co., Ltd.

+ [7]

Drug Highest PhaseApproved

First Approval Date

United States (30 Dec 1993),

Anxiety DisordersCoughDiabetic Neuropathies+ [5]

RegulationOrphan Drug (United States)

Structure/Sequence

Molecular FormulaC9H17NO2

InChIKeyUGJMXCAKCUNAIE-UHFFFAOYSA-N

CAS Registry60142-96-3

724

Clinical Trials associated with Gabapentin

NCT02219373

/ Not yet recruitingPhase 3IIT

Gabapentin and Oxcarbazepine for Chronic Neuropathic Pain in Children and Adolescents: A Double-Blind, Randomized Clinical Effectiveness Study.

Given the widespread use of anticonvulsants in the pediatric chronic pain population and the absence of scientific data supporting their use, the investigators propose a randomized, double blind, two group parallel design in which a broad group of children and adolescents with chronic neuropathic pain would be randomized to receive either Gabapentin or Oxcarbazepine.
The Primary Aim of the Study is to assess the frequencies of successful treatment of pediatric patients with neuropathic pain treated with either Gabapentin or Oxcarbazepine.
The Primary Hypotheses are as follows:
Hypothesis I: Both Gabapentin and Oxcarbazepine will result in significant reduction in pain scores when compared to each patient's baseline.
Hypothesis II: Patients who continue on active drug (Gabapentin or Oxcarbazepine) during the second phase of the trial will report greater pain reduction relative to baseline than patients who are randomized onto placebo at this randomization point.
Secondary Aims of the Study are to compare groups treated initially with Gabapentin or Oxcarbazepine with regard to reduction in pain scores (both at rest and with evoked maneuvers), functional disability scores, tolerability, and measures of mood and cognitive functioning.
Secondary Hypotheses are that Gabapentin and Oxcarbazepine differ in their effects on:
1. Pain scores at rest and with evoked maneuvers
2. Functional disability scores
3. Tolerability (frequencies of side-effects)
4. Depression and anxiety scales
5. Neuropsychological measures of cognitive processing speed, working memory, and attention.

Start Date01 Jun 2026

Sponsor / Collaborator

The Children's Hospital Corp.

ChiCTR2600123968

/ Not yet recruitingNot ApplicableIIT

Efficacy and safety of nab-paclitaxel and gemcitabine combined with gabapentin or pregabalin for neoadjuvant therapy of resectable/borderline resectable pancreatic cancer: a prospective, multicenter, open-label, single-arm clinical study.

Start Date07 May 2026

Sponsor / Collaborator

Lanzhou University Second Hospital

ChiCTR2600123743

/ Not yet recruitingNot ApplicableIIT

Comparison of the Efficacy and Safety of Mirogabalin versus Gabapentin in the Treatment of Refractory Chronic Cough: A Single-Center, Open-Label, Randomized Controlled Trial

Start Date01 Apr 2026

Sponsor / Collaborator

Tongji University

[+1]

100 Clinical Results associated with Gabapentin

100 Translational Medicine associated with Gabapentin

100 Patents (Medical) associated with Gabapentin

9,102

Literatures (Medical) associated with Gabapentin

31 Dec 2026·JOURNAL OF MEDICAL ECONOMICS

Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK

Article

Author: Kanumilli, Naresh ; Evans, Jerome ; Cattin, Juliette ; Debackere, Nele ; Osumili, Beatrice ; Buckingham, Mike ; Hunt, Barnaby ; Webb, Joanne ; Nowakowski, Piotr

INTRODUCTION:

Tirzepatide is a treatment for type 2 diabetes associated with improvements in glycemic control and weight loss, and a low risk of hypoglycemia when not used in combination with insulin or insulin secretagogues. A cost to target analysis of tirzepatide 5, 10 and 15 mg versus subcutaneous semaglutide 1 mg in the UK setting was performed, calculating the annual pharmacy cost per patient treated to six composite endpoints combining glycemic control (glycated hemoglobin [HbA1c] ≤ 6.5% [48 mmol/mol] and <7.0% [53 mmol/mol]) with weight loss (≥5%, ≥10%, ≥15%) and avoidance of hypoglycemia. The costing analysis was based on the tirzepatide costs appraised by NICE as part of TA924.

METHODS:

The proportions of patients achieving composite treatment targets with tirzepatide and semaglutide (both in combination with metformin) were taken from a post-hoc analysis of the SURPASS-2 clinical trial (N = 1,845). Costs per patient treated to target were calculated by dividing the annual treatment costs associated with each intervention by the proportion of patients achieving the treatment target with each intervention.

RESULTS:

Tirzepatide 5, 10 and 15 mg were associated with a lower pharmacy cost per patient achieving treatment target than semaglutide 1 mg for the majority of endpoints evaluated. Differences became greater at more strict treatment targets. For example, the cost per patient achieving HbA1c ≤6.5%, weight loss ≥15%, and no hypoglycemia was GBP 5,650, GBP 8,665 and GBP 9,462 lower with tirzepatide 5, 10 and 15 mg, respectively, compared with semaglutide 1 mg over a 1-year time horizon. The only endpoint where semaglutide 1 mg was associated with a lower cost per patient achieving target was HbA1c <7.0%, weight loss ≥5%, and no hypoglycemia.

CONCLUSIONS:

Compared to semaglutide, tirzepatide was associated with a lower annual pharmacy cost per patient with diabetes achieving treatment target in the UK for the majority of endpoints, with greater differences at more strict treatment targets.

31 Dec 2026·COPD-Journal of Chronic Obstructive Pulmonary Disease

Prescribing Patterns of Gabapentinoids in Patients with Chronic Obstructive Pulmonary Disorder

Article

Author: Bullock, Reece ; Dimit, Alexandra ; Patel, Manysha ; Englehart, Anika ; Soric, Mate Michael ; King, Olivia ; Bole, Kelly ; Mara, Nita ; Vergara, Mollie ; Moqbl, Amgad ; Skory, Brandon

In 2019, the U.S. Food and Drug Administration (FDA) issued a warning regarding the risk of serious respiratory depression in patients using gabapentin or pregabalin who have respiratory risk factors, including those with chronic obstructive pulmonary disorder (COPD). With the overall prescribing of gabapentinoids continuing to grow, there is the potential for inappropriate prescribing in this patient population. Data from the National Ambulatory Medical Care Survey (NAMCS) from 2013 to 2018, with the exception of 2017, was used to assess prevalence and predictors of gabapentinoid prescribing in patients with COPD. The data consists of 1,131 unweighted visits, representing approximately 53.6 million ambulatory care visits nationally. Of these visits, 146 patients (10.8%) with a COPD diagnosis were also prescribed a gabapentinoid, which represents more than a million office visits annually when weighted. Patients with an increased risk of receiving gabapentinoids were those with concomitant diabetes mellitus, concurrent opioid use, and those currently using tobacco. Due to increased risk of serious respiratory depression caused by gabapentinoids, prescribers should take caution when prescribing to individuals with COPD and other respiratory risk factors. Based on the reviewed prescribing patterns, more education is needed to inform providers about the risks associated with concomitant COPD and gabapentinoid use.

01 Dec 2026·MOLECULAR BIOLOGY REPORTS

Bergenin attenuates neuropathic pain by modulation of TRPV1/CGRP signalling and neuro-inflammatory mechanisms

Article

Author: Kotiyal, Akhilesh ; Gadepalli, Anagha ; Anmol ; Sharma, Dilip ; Chouhan, Deepak ; Tiwari, Vinod

BACKGROUND AND PURPOSE:

Neuropathic pain is a chronic and disabling condition characterized by persistent sensory hypersensitivity and inadequate treatment options. Neuroinflammation and TRPV1/CGRP-driven nociceptive pathways are critical contributors to its pathogenesis. Bergenin, a naturally occurring C-glucoside with established anti-inflammatory and antioxidant activities, may offer a promising therapeutic approach.

EXPERIMENTAL APPROACH:

Neuropathic pain was induced in rats using the chronic constriction injury (CCI) model. Bergenin (25, 50, and 100 mg/kg, i.p.) and gabapentin (30 mg/kg, i.p.) were administered. Nociceptive behaviors were evaluated using von Frey, paintbrush, pinprick, Hargreaves, acetone spray, and ice floor tests. Locomotor activity and motor coordination were assessed to examine CNS safety. Oxidative stress parameters and the expression of TNF-α, IBA1, ICAM1, TRPV1, and CGRP were measured in spinal cord tissue.

KEY RESULTS:

CCI produced marked mechanical, thermal, and cold hypersensitivity, accompanied by elevated oxidative stress and increased neuroinflammatory marker expression. Bergenin significantly attenuated pain-related behaviors across all tested doses, with enhanced efficacy at higher doses, and improved oxido-nitrosative status. Furthermore, it downregulated TNF-α, IBA1, ICAM1, TRPV1, and CGRP expression while producing no detectable impairment in locomotor activity or motor coordination.

CONCLUSION AND IMPLICATIONS:

Bergenin alleviates neuropathic pain by modulating neuroinflammatory pathways and TRPV1/CGRP signaling while reducing oxido-nitrosative stress, without affecting locomotor activity or motor coordination. These findings support its potential as a non-opioid therapeutic strategy for the management of neuropathic pain.

News (Medical) associated with Gabapentin

17 Jun 2026

·www.biospace.com

MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy

Randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, and dose-response efficacy of oral Ketamir-2 at a leading U.S. cancer center MIAMI, FL / ACCESS Newswire / June 17, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company") , a clinical-stage pharmaceutical company developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced the submission of a Phase 2a clinical trial protocol to the U.S. Food and Drug Administration (FDA) for Ketamir-2, the Company's proprietary oral NMDA receptor modulator, in chemotherapy-induced peripheral neuropathy (CIPN). Addressing a Significant Unmet Medical Need Chemotherapy-induced peripheral neuropathy is one of the most common and debilitating consequences of cancer treatment. It affects an estimated 30 to 40 percent of patients who receive neurotoxic chemotherapy, and approximately 3 million new persistent cases are estimated annually worldwide. For many patients, symptoms including pain, numbness, tingling, and loss of sensation do not resolve when treatment ends. Roughly 30 percent continue to experience them six months or more after completing chemotherapy, often with lasting impact on their ability to function and their overall quality of life. Despite how common and disabling the condition is, there are currently no FDA-approved therapies specifically for CIPN. Oncologists rely on medications such as gabapentin, pregabalin, duloxetine, and tricyclic antidepressants, none of which were developed for this purpose, and many of which provide incomplete relief. In severe cases, CIPN forces dose reductions or the discontinuation of chemotherapy entirely, potentially compromising cancer outcomes. The absence of an approved treatment has remained one of the more glaring gaps in oncology supportive care. About the Phase 2a Study (Protocol Mira-002) The planned Phase 2a study is a randomized, double-blind, placebo-controlled, three-period crossover trial that will evaluate the safety, tolerability, and dose-response relationship of oral Ketamir-2 in patients with moderate-to-severe persistent CIPN. The study will be conducted at a leading U.S. cancer center. Patients will be enrolled and randomized to receive Ketamir-2 at one of two dose levels, 300 mg or 600 mg, or a matching placebo, across three sequential seven-day treatment periods, each separated by a two-week washout. Because each patient moves through all three treatment sequences, the crossover design allows each participant to serve as their own control, producing a more reliable signal with a smaller study population. The primary objectives are to characterize the safety and tolerability of Ketamir-2 at both dose levels and to evaluate its dose-response relationship on neuropathic pain intensity, measured by change from baseline in the weekly mean 11-point Numeric Rating Scale pain score. Secondary objectives include the proportion of patients achieving meaningful pain reductions of 30 percent or more and 50 percent or more, changes in CIPN-related symptoms and functional status measured by the EORTC QLQ-CIPN20, and assessment of central nervous system pharmacodynamic effects. Each participant will be in the study for up to 82 days. To be eligible, patients must have experienced persistent CIPN for at least three months following chemotherapy, report a baseline pain score of 4 or higher on the NRS scale, and have underlying cancer that is clinically stable with no active disease requiring systemic treatment at study entry. The submission builds on results from the successfully completed MIRA-001 Phase 1 study, which enrolled 56 healthy volunteers across single and multiple ascending dose cohorts. No serious adverse events or dose-limiting toxicities were observed at any dose tested, and the pharmacokinetic pro the dose levels and once-daily administration schedule selected for Phase 2a. Management Commentary "CIPN has been overlooked for too long," said Erez Aminov, Chairman and Chief Executive Officer of MIRA Pharmaceuticals . "Millions of cancer survivors are managing real, ongoing pain with medications that were never approved for this condition and that often do not work well enough. Ketamir-2 came out of Phase 1 with a clean safety record, and this Phase 2a study is the next step toward building the evidence base the program needs." Dr. Itzchak Angel, Chief Scientific Advisor of MIRA Pharmaceuticals , commented: "The crossover design we selected for this study is scientifically well-suited to this patient population. Having each participant experience all three treatment periods gives us a more precise read on dose-response while keeping the study size manageable. The Phase 1 data gave us clear guidance on dosing, and Phase 2a is designed to answer the questions that matter most going forward - how Ketamir-2 performs on safety and pain relief in patients who need it." About Ketamir-2 Ketamir-2 is an oral NMDA receptor modulator in development for chronic neuropathic pain. The NMDA receptor pathway is well established in neuropathic pain biology, and ketamine has long demonstrated activity there, but its use for chronic conditions has been constrained by the need for intravenous administration, significant dissociative side effects, Schedule III controlled substance status, and the clinical infrastructure required to administer and monitor it. Ketamir-2 was built to capture the mechanism without those limitations, delivered orally, dosed once daily, and confirmed by the DEA as non-scheduled. MIRA holds exclusive worldwide rights to Ketamir-2 with intellectual property secured across 10 major markets, including the United States, European Union, China, Japan, Canada, Australia, India, Israel, Mexico, and South Korea. Ketamir-2 has not been approved by the U.S. Food and Drug Administration for any indication. Its safety and efficacy have not been established. About MIRA Pharmaceuticals, Inc. MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of investigational therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates being evaluated for neuropathic pain, inflammatory pain, obesity, addiction-related disorders, anxiety, and cognitive impairment. For more information, please visit . Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "can," "could," "would," "may," "will," "believe," "estimate," "forecast," "goal," "project," "guidance," "potential," "intend," "seek," "target" and other words of similar meaning, although not all forward-looking statements include these words. Forward-looking statements may include, but are not limited to, statements regarding the development of Ketamir-2; the planned Phase 2a clinical trial, including its design, objectives, enrollment, timing, initiation and potential outcomes; the potential efficacy, safety, tolerability and therapeutic benefits of Ketamir-2; the potential advantages of Ketamir-2 compared to existing treatment options; the potential market opportunity for Ketamir-2; future regulatory interactions; intellectual property protection; strategic partnership opportunities; and the future development and commercialization of Ketamir-2. These forward-looking statements are based on current expectations, estimates, forecasts, and projections, as well as management's beliefs and assumptions, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to preclinical and clinical development, the ability to obtain regulatory approvals, the outcome of future studies, reliance on third parties, intellectual property protection, financing needs, market conditions, and the other risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K and the Company's other filings with the U.S. Securities and Exchange Commission ("SEC"). Forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update or revise such statements, whether as a result of new information, future events, or otherwise, except as required by applicable law. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at the SEC website and in the "Investors" section of our website at MIRA Investors, for a discussion of these and other risks and uncertainties. Contact: Krystina Quintana info@mirapharma.com (786) 432-9792 SOURCE: MIRA Pharmaceuticals View the original press release on ACCESS Newswire

Phase 2Phase 1Clinical Result

12 Jun 2026

·www.prnewswire.com

Braeburn to Present Research at CPDD 2026 Annual Meeting, Including Data on Withdrawal Suppression and Real-World Treatment Retention in Patients With Opioid Use Disorder

PLYMOUTH MEETING, Pa., June 12, 2026 /PRNewswire/ -- Braeburn today announced it will present two oral presentations and two posters at the 88th Annual Scientific Meeting of the College on Problems of Drug Dependence (CPDD), taking place June 13–17, 2026, in Portland, Oregon, expanding the clinical and real-world evidence base for BRIXADI® (buprenorphine) extended-release injection for subcutaneous use (CIII) in the fentanyl era. Oral Presentations: First Dose Withdrawal Suppression With Injectable Weekly and Monthly Buprenorphine (CAM2038) and the Relationship Between Buprenorphine Plasma Concentrations and Withdrawal Suppression in Participants With Opioid Use Disorder This presentation will share findings from a post hoc analysis evaluating the first dose effect of Weekly and Monthly BRIXADI on opioid withdrawal and self-reported illicit drug use in participants with moderate to severe OUD and the association between buprenorphine plasma concentrations and withdrawal suppression. Late-Breaking: Office-Based Treatment Retention Among Patients With OUD and Recent Fentanyl Use: Extended-Release Injectable Buprenorphine vs Sublingual Buprenorphine This presentation will share findings from a real-world retrospective analysis of electronic medical record data examining treatment retention among patients with OUD and recent fentanyl use who received BRIXADI compared to those on sublingual buprenorphine over a 6-month observation period. Posters: Real-World Utilization Trends of Weekly and Monthly Injectable Buprenorphine (CAM2038) in the United States During the Era of High Potency Synthetic Opioids A retrospective analysis of specialty pharmacy dispensing data for BRIXADI evaluated the distribution of available doses and formulations and longitudinal utilization trends since becoming available in the United States. National and Regional Trends in Fentanyl-Associated Polysubstance Use: A Cross-Sectional Analysis of Urine Drug Testing in the United States, 2016–2025 A retrospective, cross-sectional analysis of definitive urine drug testing results examined national and regional patterns of concomitant drug use over time among patients with substance use disorders in the United States who use fentanyl. About BRIXADI® BRIXADI is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine. BRIXADI should be used as part of a complete treatment plan that includes counseling and psychosocial support. IMPORTANT SAFETY INFORMATION WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; BRIXADI RISK EVALUATION AND MITIGATION STRATEGY Serious harm or death could result if administered intravenously. BRIXADI forms a liquid crystalline gel upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life-threatening pulmonary emboli, if administered intravenously. Because of the risk of serious harm or death that could result from intravenous self-administration, BRIXADI is only available through a restricted program called the BRIXADI REMS. Healthcare settings and pharmacies that order and dispense BRIXADI must be certified in this program and comply with the REMS requirements. BRIXADI (buprenorphine) extended-release injection (weekly, 50 mg/mL buprenorphine) and BRIXADI (monthly, 356 mg/mL buprenorphine) are different formulations. Doses of BRIXADI (weekly) cannot be combined to yield an equivalent monthly dose. CONTRAINDICATIONS BRIXADI is contraindicated in patients with hypersensitivity (e.g., anaphylactic shock) to buprenorphine or any other ingredients in the solution for injection. WARNINGS AND PRECAUTIONS Addiction, Abuse, and Misuse: BRIXADI contains buprenorphine, a Schedule III controlled substance that can be abused in a manner similar to other opioids. Buprenorphine is sought by people with opioid use disorder and is subject to criminal diversion. Monitor all patients for progression of opioid dependence and addictive behaviors. Life-Threatening Respiratory and Central Nervous System (CNS) Depression: Buprenorphine has been associated with life-threatening respiratory depression and death. Use BRIXADI with caution in patients with compromised respiratory function. Due to its extended-release characteristics, if BRIXADI is discontinued as a result of compromised respiratory function, monitor patients for ongoing buprenorphine effects for approximately 1 month for BRIXADI (weekly) and for approximately 4 months for BRIXADI (monthly). Educate patients and caregivers on how to recognize respiratory depression and emphasize the importance of calling 911 or getting emergency medical help right away in the event of a known or suspected overdose. Patient Access to an Opioid Overdose Reversal Agent for the Emergency Treatment of Opioid Overdose: Inform patients and caregivers about opioid overdose reversal agents (e.g., naloxone, nalmefene) and discuss the importance of having access to an opioid overdose reversal agent. Because patients being treated for opioid use disorder have the potential for relapse, putting them at risk for opioid overdose, strongly consider prescribing or recommending an opioid overdose reversal agent for the emergency treatment of an opioid overdose, both when initiating and renewing treatment with BRIXADI. If an opioid overdose reversal agent is prescribed, educate patients and caregivers on how to treat with such an agent, and emphasize the importance of calling 911 or getting emergency medical help, even if an agent is administered. Concomitant Use of Benzodiazepines or other CNS Depressants: Concomitant use of buprenorphine and benzodiazepines or other CNS depressants (e.g., alcohol, non-benzodiazepine sedative/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, gabapentinoids [gabapentin or pregabalin], and other opioids) increases the risk of adverse reactions including overdose, respiratory depression, and death. Ensure that other healthcare providers prescribing benzodiazepines or other CNS depressants are aware of the patient's buprenorphine treatment and coordinate care to minimize the risk associated with concomitant use. Inform patients and caregivers that potentially fatal additive effects may occur if BRIXADI is used with benzodiazepines or other CNS depressants, including alcohol, and not to use these concomitantly unless supervised by a healthcare provider. Neonatal Opioid Withdrawal Syndrome, Pregnancy, and Lactation: Neonatal opioid withdrawal syndrome (NOWS) is an expected and treatable outcome of prolonged use of opioids during pregnancy. NOWS may be life-threatening if not recognized and treated in the neonate. Healthcare providers should observe newborns for signs of NOWS and manage accordingly. Advise pregnant women receiving opioid addiction treatment with BRIXADI of the risk of neonatal opioid withdrawal syndrome. Warn patients that buprenorphine passes into breast milk. Advise the nursing mother taking buprenorphine to monitor the infant for increased drowsiness and breathing difficulties. Adrenal Insufficiency: If adrenal insufficiency is diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid. Risk of Opioid Withdrawal with Abrupt Discontinuation: Patients who elect to discontinue BRIXADI treatment should be monitored for withdrawal signs and symptoms with consideration given to the product's extended-release characteristics. Risk of Hepatitis, Hepatic Events, and Use in Patients with Impaired Hepatic Function: Liver function tests should be performed on all patients prior to initiation, during treatment, and if a hepatic event is suspected. Because buprenorphine levels cannot be rapidly decreased, patients with pre‐existing moderate to severe hepatic impairment are not candidates for treatment with BRIXADI. Patients who develop moderate to severe hepatic impairment while being treated with BRIXADI should be monitored for signs and symptoms of toxicity or overdose of buprenorphine and may require a dose adjustment. Hypersensitivity Reactions: Cases of bronchospasm, angioneurotic edema, and anaphylactic shock have been reported in patients receiving buprenorphine-containing products. The most common signs and symptoms include rashes, hives, and pruritus. The BRIXADI needle cap is synthetically derived from natural rubber latex which may cause allergic reactions in latex-sensitive individuals. Precipitation of Opioid Withdrawal in Patients Dependent on Full Opioid Agonists: BRIXADI injection may precipitate opioid withdrawal signs and symptoms in individuals physically dependent on full opioid agonists such as heroin, morphine, or methadone before the effects of the full opioid agonist have subsided. In patients who are new entrants to treatment, to avoid precipitating an opioid withdrawal syndrome, administer a 4 mg test dose of transmucosal buprenorphine when objective signs of mild to moderate withdrawal appear and monitor for precipitated withdrawal before injecting BRIXADI. Risks Associated with Treatment of Emergent Acute Pain: While on BRIXADI, situations may arise where patients need acute pain management, or may require anesthesia. Treat patients receiving BRIXADI with non-opioid analgesic whenever possible. Patients requiring opioid therapy for analgesia may be treated with a high-affinity full opioid analgesic under the supervision of a healthcare provider, with particular attention to respiratory function. Higher doses may be required for analgesic effect. Therefore, a higher potential for toxicity exists with opioid administration. Advise patients of the importance of instructing their family members, in the event of emergency, to inform the treating healthcare provider or emergency room staff that the patient is being treated with BRIXADI. Use in Opioid Naïve Patients: There have been reported deaths of opioid naïve individuals who received a 2 mg dose of buprenorphine as a sublingual tablet. BRIXADI is not appropriate for use in opioid naïve patients. Patients at Risk for Arrhythmia: Thorough QT studies with buprenorphine products have demonstrated QT prolongation ≤ 15 msec. This QTc prolongation effect does not appear to be mediated by hERG channels. Based on these two findings, buprenorphine is unlikely to be pro-arrhythmic when used alone in patients without risk factors. The risk of combining buprenorphine with other QT-prolonging agents is not known. Impairment of Ability to Drive and Operate Machinery: BRIXADI may impair the mental or physical abilities required for the performance of potentially dangerous tasks such as driving a car or operating machinery. Caution patients about driving or operating hazardous machinery until they are reasonably certain that BRIXADI does not adversely affect their ability to engage in such activities. Orthostatic Hypotension: Buprenorphine may produce orthostatic hypotension in ambulatory patients. Elevation of Cerebrospinal Fluid Pressure: Buprenorphine may elevate cerebrospinal fluid pressure and should be used with caution in patients with head injury, intracranial lesions, and other circumstances when cerebrospinal pressure may be increased. Elevation of Intracholedochal Pressure: Buprenorphine has been shown to increase intracholedochal pressure, as do other opioids, and thus should be administered with caution to patients with dysfunction of the biliary tract. Effects in Acute Abdominal Conditions: Buprenorphine may obscure the diagnosis or clinical course of patients with acute abdominal conditions. Unintentional Pediatric Exposure: Buprenorphine can cause severe, possibly fatal, respiratory depression in children who are accidentally exposed to it. ADVERSE REACTIONS Adverse reactions commonly associated with BRIXADI administration (in ≥5% of patients) were injection site pain, headache, constipation, nausea, injection site erythema, injection site pruritus, insomnia, and urinary tract infection. DRUG INTERACTIONS CYP3A4 Inhibitors and Inducers: Monitor patients starting or ending CYP3A4 inhibitors or inducers for potential over or under dosing. Serotonergic Drugs: If concomitant use is warranted, monitor for serotonin syndrome, particularly during treatment initiation, and during dose adjustment of the serotonergic drug. USE IN SPECIFIC POPULATIONS Lactation: Buprenorphine passes into the mother's milk. The development and health benefits of breastfeeding should be considered along with the mother's clinical need for buprenorphine treatment and any potential adverse effects on the breastfed child from the drug or from the underlying maternal condition. Geriatric Patients: Monitor geriatric patients receiving BRIXADI for sedation or respiratory depression. Moderate to Severe Hepatic Impairment: BRIXADI is not recommended for use in patients with pre-existing moderate to severe hepatic impairment. To report SUSPECTED ADVERSE REACTIONS, contact Braeburn at 1-833-274-9234 or FDA at 1-800-FDA-1088 or . Please see the BRIXADI Medication Guide and Full Prescribing Information , including BOXED WARNING, at BRIXADI.com or accompanying this document. About Braeburn Braeburn is dedicated to delivering solutions for people living with the serious consequences of opioid use disorder. At Braeburn, we challenge the status quo and champion transformation of the management of opioid use disorder (OUD) by partnering with the community to create a world where every person with OUD gets the best possible care and opportunity to reach their full potential. Visit braeburnrx.com to learn more. Connect with Braeburn on LinkedIn at linkedin.com/company/braeburn. For additional information, please contact: Sabrina Romano, Senior Manager of Corporate Communications & Advocacy, at [email protected] BRX-1802 June 2026 SOURCE Braeburn 21% more press release views with Request a Demo

Phase 3Clinical ResultDrug Approval

28 May 2026

·www.prnewswire.com

Braeburn Presents New Data at 2026 ASCP Annual Meeting Demonstrating Opioid Withdrawal Suppression at Low Buprenorphine Plasma Concentrations

PLYMOUTH MEETING, Pa., May 28, 2026 /PRNewswire/ -- Braeburn Inc. today announced the presentation of three posters at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami, FL, adding to the growing body of clinical and real-world evidence related to the use of Weekly and Monthly BRIXADI® (buprenorphine) extended-release injection for subcutaneous use (CIII) for the treatment of moderate to severe opioid use disorder (OUD). Poster Highlights First Dose Treatment Effects With Injectable Weekly and Monthly Buprenorphine (CAM2038) and the Relationship Between Buprenorphine Plasma Concentrations and Withdrawal Suppression in Participants With Opioid Use Disorder A post-hoc analysis (N=110) evaluating first dose treatment effects of CAM2038 32 mg weekly and 128 mg monthly and the association between buprenorphine plasma concentrations and opioid withdrawal suppression observed: Suppression of opioid withdrawal following a single dose CAM2038 32 mg weekly and 128 mg monthly, which was sustained throughout the dosing interval, including in participants with buprenorphine plasma concentrations <0.5 ng/mL. No meaningful association between buprenorphine plasma concentration and opioid withdrawal suppression across study time points. This analysis was post-hoc and exploratory and was not prospectively designed to evaluate the relationship between plasma concentrations and withdrawal suppression. 2. Real-World Utilization Trends of Weekly and Monthly Injectable Buprenorphine (CAM2038) in the United States During the Era of High-Potency Synthetic Opioids A retrospective analysis of real-world specialty pharmacy data (N=30,038) found: Utilization of all available doses of BRIXADI Weekly (8 mg: 15.7%, 16 mg: 18.6%, 24 mg: 36.1%, 32 mg: 29.6% of 61,087 units dispensed) and Monthly (64 mg: 20.5%, 96 mg: 35.2%, 128 mg: 44.4% of 173,082 units dispensed). Some patients (29.6%) changed doses over time and many BRIXADI Weekly initiators (60.8%) were later dispensed BRIXADI Monthly. These findings are consistent with clinical practice guidelines that promote individualized dosing; however, the data reflect medication dispensed and may not fully capture treatment outcomes. 3. Office-Based Treatment Retention Among Patients With Opioid Use Disorder and Recent Fentanyl Use: Extended-Release Injectable Buprenorphine vs Sublingual Buprenorphine A retrospective cohort study evaluating patients with OUD and recent fentanyl use treated with BRIXADI (n=162) or sublingual buprenorphine (n=486) through a national outpatient network of addiction clinics revealed: Treatment with BRIXADI was associated with greater retention on buprenorphine over 6 months compared to sublingual buprenorphine (log-rank test, P<0.001). Retention rates were higher in the BRIXADI cohort than in the sublingual buprenorphine cohort at Day 30 (51.9% vs 25.5%), Day 90 (31.5% vs 11.7%), and Day 180 (20.4% vs 7.2%). The electronic medical record data evaluated were derived from a national outpatient network of addiction clinics and may lack generalizability to other treatment settings. "For too long, treatment decisions have been shaped by older research that may not reflect the full picture of how buprenorphine works, particularly as the opioid crisis has evolved with the rise of high-potency synthetic opioids," said Joshua M. Cohen, MD, MPH, FAHS, Chief Medical Officer at Braeburn. "Data like these contribute to a more robust evidence base that may help inform individualized treatment decisions for people living with moderate to severe OUD." About BRIXADI® BRIXADI is a prescription medicine for treating people with moderate to severe opioid addiction who have started treatment with a single dose of buprenorphine as a sublingual tablet or buccal film or who are already receiving buprenorphine treatment. BRIXADI should be used along with counseling and behavioral therapy. IMPORTANT SAFETY INFORMATION WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; BRIXADI RISK EVALUATION AND MITIGATION STRATEGY Serious harm or death could result if administered intravenously. BRIXADI forms a liquid crystalline gel upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life-threatening pulmonary emboli, if administered intravenously. Because of the risk of serious harm or death that could result from intravenous self-administration, BRIXADI is only available through a restricted program called the BRIXADI REMS. Healthcare settings and pharmacies that order and dispense BRIXADI must be certified in this program and comply with the REMS requirements. BRIXADI (buprenorphine) extended-release injection (weekly, 50 mg/mL buprenorphine) and BRIXADI (monthly, 356 mg/mL buprenorphine) are different formulations. Doses of BRIXADI (weekly) cannot be combined to yield an equivalent monthly dose. CONTRAINDICATIONS BRIXADI is contraindicated in patients with hypersensitivity (e.g., anaphylactic shock) to buprenorphine or any other ingredients in the solution for injection. WARNINGS AND PRECAUTIONS Addiction, Abuse, and Misuse: BRIXADI contains buprenorphine, a Schedule III controlled substance that can be abused in a manner similar to other opioids. Buprenorphine is sought by people with opioid use disorder and is subject to criminal diversion. Monitor all patients for progression of opioid dependence and addictive behaviors. Life-Threatening Respiratory and Central Nervous System (CNS) Depression: Buprenorphine has been associated with life-threatening respiratory depression and death. Use BRIXADI with caution in patients with compromised respiratory function. Due to its extended-release characteristics, if BRIXADI is discontinued as a result of compromised respiratory function, monitor patients for ongoing buprenorphine effects for approximately 1 month for BRIXADI (weekly) and for approximately 4 months for BRIXADI (monthly). Educate patients and caregivers on how to recognize respiratory depression and emphasize the importance of calling 911 or getting emergency medical help right away in the event of a known or suspected overdose. Patient Access to an Opioid Overdose Reversal Agent for the Emergency Treatment of Opioid Overdose: Inform patients and caregivers about opioid overdose reversal agents (e.g., naloxone, nalmefene) and discuss the importance of having access to an opioid overdose reversal agent. Because patients being treated for opioid use disorder have the potential for relapse, putting them at risk for opioid overdose, strongly consider prescribing or recommending an opioid overdose reversal agent for the emergency treatment of an opioid overdose, both when initiating and renewing treatment with BRIXADI. If an opioid overdose reversal agent is prescribed, educate patients and caregivers on how to treat with such an agent, and emphasize the importance of calling 911 or getting emergency medical help, even if an agent is administered. Concomitant Use of Benzodiazepines or other CNS Depressants: Concomitant use of buprenorphine and benzodiazepines or other CNS depressants (e.g., alcohol, non-benzodiazepine sedative/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, gabapentinoids [gabapentin or pregabalin], and other opioids) increases the risk of adverse reactions including overdose, respiratory depression, and death. Ensure that other healthcare providers prescribing benzodiazepines or other CNS depressants are aware of the patient's buprenorphine treatment and coordinate care to minimize the risk associated with concomitant use. Inform patients and caregivers that potentially fatal additive effects may occur if BRIXADI is used with benzodiazepines or other CNS depressants, including alcohol, and not to use these concomitantly unless supervised by a healthcare provider. Neonatal Opioid Withdrawal Syndrome, Pregnancy, and Lactation: Neonatal opioid withdrawal syndrome (NOWS) is an expected and treatable outcome of prolonged use of opioids during pregnancy. NOWS may be life-threatening if not recognized and treated in the neonate. Healthcare providers should observe newborns for signs of NOWS and manage accordingly. Advise pregnant women receiving opioid addiction treatment with BRIXADI of the risk of neonatal opioid withdrawal syndrome. Warn patients that buprenorphine passes into breast milk. Advise the nursing mother taking buprenorphine to monitor the infant for increased drowsiness and breathing difficulties. Adrenal Insufficiency: If adrenal insufficiency is diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid. Risk of Opioid Withdrawal with Abrupt Discontinuation: Patients who elect to discontinue BRIXADI treatment should be monitored for withdrawal signs and symptoms with consideration given to the product's extended-release characteristics. Risk of Hepatitis, Hepatic Events, and Use in Patients with Impaired Hepatic Function: Liver function tests should be performed on all patients prior to initiation, during treatment, and if a hepatic event is suspected. Because buprenorphine levels cannot be rapidly decreased, patients with pre‐existing moderate to severe hepatic impairment are not candidates for treatment with BRIXADI. Patients who develop moderate to severe hepatic impairment while being treated with BRIXADI should be monitored for signs and symptoms of toxicity or overdose of buprenorphine and may require a dose adjustment. Hypersensitivity Reactions: Cases of bronchospasm, angioneurotic edema, and anaphylactic shock have been reported in patients receiving buprenorphine-containing products. The most common signs and symptoms include rashes, hives, and pruritus. The BRIXADI needle cap is synthetically derived from natural rubber latex which may cause allergic reactions in latex-sensitive individuals. Precipitation of Opioid Withdrawal in Patients Dependent on Full Opioid Agonists: BRIXADI injection may precipitate opioid withdrawal signs and symptoms in individuals physically dependent on full opioid agonists such as heroin, morphine, or methadone before the effects of the full opioid agonist have subsided. In patients who are new entrants to treatment, to avoid precipitating an opioid withdrawal syndrome, administer a 4 mg test dose of transmucosal buprenorphine when objective signs of mild to moderate withdrawal appear and monitor for precipitated withdrawal before injecting BRIXADI. Risks Associated with Treatment of Emergent Acute Pain: While on BRIXADI, situations may arise where patients need acute pain management, or may require anesthesia. Treat patients receiving BRIXADI with non-opioid analgesic whenever possible. Patients requiring opioid therapy for analgesia may be treated with a high-affinity full opioid analgesic under the supervision of a healthcare provider, with particular attention to respiratory function. Higher doses may be required for analgesic effect. Therefore, a higher potential for toxicity exists with opioid administration. Advise patients of the importance of instructing their family members, in the event of emergency, to inform the treating healthcare provider or emergency room staff that the patient is being treated with BRIXADI. Use in Opioid Naïve Patients: There have been reported deaths of opioid naïve individuals who received a 2 mg dose of buprenorphine as a sublingual tablet. BRIXADI is not appropriate for use in opioid naïve patients. Patients at Risk for Arrhythmia: Thorough QT studies with buprenorphine products have demonstrated QT prolongation ≤ 15 msec. This QTc prolongation effect does not appear to be mediated by hERG channels. Based on these two findings, buprenorphine is unlikely to be pro-arrhythmic when used alone in patients without risk factors. The risk of combining buprenorphine with other QT-prolonging agents is not known. Impairment of Ability to Drive and Operate Machinery: BRIXADI may impair the mental or physical abilities required for the performance of potentially dangerous tasks such as driving a car or operating machinery. Caution patients about driving or operating hazardous machinery until they are reasonably certain that BRIXADI does not adversely affect their ability to engage in such activities. Orthostatic Hypotension: Buprenorphine may produce orthostatic hypotension in ambulatory patients. Elevation of Cerebrospinal Fluid Pressure: Buprenorphine may elevate cerebrospinal fluid pressure and should be used with caution in patients with head injury, intracranial lesions, and other circumstances when cerebrospinal pressure may be increased. Elevation of Intracholedochal Pressure: Buprenorphine has been shown to increase intracholedochal pressure, as do other opioids, and thus should be administered with caution to patients with dysfunction of the biliary tract. Effects in Acute Abdominal Conditions: Buprenorphine may obscure the diagnosis or clinical course of patients with acute abdominal conditions. Unintentional Pediatric Exposure: Buprenorphine can cause severe, possibly fatal, respiratory depression in children who are accidentally exposed to it. ADVERSE REACTIONS Adverse reactions commonly associated with BRIXADI administration (in ≥5% of patients) were injection site pain, headache, constipation, nausea, injection site erythema, injection site pruritus, insomnia, and urinary tract infection. DRUG INTERACTIONS CYP3A4 Inhibitors and Inducers: Monitor patients starting or ending CYP3A4 inhibitors or inducers for potential over or under dosing. Serotonergic Drugs: If concomitant use is warranted, monitor for serotonin syndrome, particularly during treatment initiation, and during dose adjustment of the serotonergic drug. USE IN SPECIFIC POPULATIONS Lactation: Buprenorphine passes into the mother's milk. The development and health benefits of breastfeeding should be considered along with the mother's clinical need for buprenorphine treatment and any potential adverse effects on the breastfed child from the drug or from the underlying maternal condition. Geriatric Patients: Monitor geriatric patients receiving BRIXADI for sedation or respiratory depression. Moderate to Severe Hepatic Impairment: BRIXADI is not recommended for use in patients with pre-existing moderate to severe hepatic impairment. To report SUSPECTED ADVERSE REACTIONS, contact Braeburn at 1-833-274-9234 or FDA at 1-800-FDA-1088 or . Please see the BRIXADI Medication Guide and Full Prescribing Information , including BOXED WARNING, at BRIXADI.com or accompanying this document. About Braeburn Braeburn is dedicated to delivering solutions for people living with the serious consequences of opioid use disorder. At Braeburn, we challenge the status quo and champion transformation of the management of opioid use disorder (OUD) by partnering with the community to create a world where every person with OUD gets the best possible care and opportunity to reach their full potential. Visit braeburnrx.com to learn more. Connect with Braeburn on LinkedIn at linkedin.com/company/braeburn. For additional information, please contact: Sabrina Romano, Senior Manager of Corporate Communications & Advocacy, at [email protected] BRX-1759 April 2026 SOURCE Braeburn 21% more press release views with Request a Demo

Clinical ResultASCOPhase 3Drug Approval

100 Deals associated with Gabapentin

External Link

KEGG	Wiki	ATC	Drug Bank
D00332	Gabapentin	N03AX12	DB00996

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Peripheral neuralgia	Belgium	Viatris Pharma GmbH	27 Oct 2006
Peripheral neuralgia	Czechia	Viatris Pharma GmbH	27 Oct 2006
Peripheral neuralgia	France	Viatris Pharma GmbH	27 Oct 2006
Peripheral neuralgia	Germany	Viatris Pharma GmbH	27 Oct 2006
Peripheral neuralgia	Hungary	Viatris Pharma GmbH	27 Oct 2006
Peripheral neuralgia	Iceland	Viatris Pharma GmbH	27 Oct 2006
Peripheral neuralgia	Ireland	Viatris Pharma GmbH	27 Oct 2006
Peripheral neuralgia	Italy	Viatris Pharma GmbH	27 Oct 2006
Peripheral neuralgia	Latvia	Viatris Pharma GmbH	27 Oct 2006
Peripheral neuralgia	Luxembourg	Viatris Pharma GmbH	27 Oct 2006
Peripheral neuralgia	Netherlands	Viatris Pharma GmbH	27 Oct 2006
Peripheral neuralgia	Norway	Viatris Pharma GmbH	27 Oct 2006
Peripheral neuralgia	Poland	Viatris Pharma GmbH	27 Oct 2006
Peripheral neuralgia	Portugal	Viatris Pharma GmbH	27 Oct 2006
Peripheral neuralgia	Slovenia	Viatris Pharma GmbH	27 Oct 2006
Peripheral neuralgia	Sweden	Viatris Pharma GmbH	27 Oct 2006
Peripheral neuralgia	United Kingdom	Viatris Pharma GmbH	27 Oct 2006
Neuralgia, Postherpetic	United States	Viatris Specialty LLC	02 Mar 2000
Anxiety Disorders	Japan	Pfizer Inc.	30 Dec 1993
Cough	Japan	Pfizer Inc.	30 Dec 1993

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Analgesia	NDA/BLA	Canada	Rubicon Research Ltd.	01 Nov 2025
Dyspepsia	Phase 3	United States	Pfizer Inc.	01 Mar 2010
Refractory chronic cough	Phase 3	Australia	Hunter New England Area Health Service	15 Oct 2008
Hot Flashes	Phase 3	United States	Assertio Therapeutics, Inc.	01 Sep 2008
Vasomotor symptom	Phase 3	United States	Assertio Therapeutics, Inc.	01 Sep 2008
Sleep Initiation and Maintenance Disorders	Phase 3	United States	Viatris, Inc.	01 Oct 2004
Tremor	Phase 3	United States	Pfizer Inc.	01 Mar 2004
Carpal Tunnel Syndrome	Phase 3	Hong Kong	Pfizer Inc.	01 Oct 2003
Amyotrophic Lateral Sclerosis	Phase 3	United States	Pfizer Inc.	31 Dec 1999
Herpes Labialis	Phase 1	Belgium	Pfizer Inc.	01 Jul 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03220776 (Pubmed \| Transl Psychiatry)	Phase 2	Alcohol Use Disorder	54	N-acetylcysteine (NAC)	jjbgqpvcqf(mkurbyzzkj) = ramivepswr svlpgaaaxe (ihubwpjctw, 4.6) View more	Positive	03 Jun 2026
				Placebo	jjbgqpvcqf(mkurbyzzkj) = leyagwgbjg svlpgaaaxe (ihubwpjctw, 4.55) View more
NCT05076110 (CTgov)	Phase 4	Pain	86	Oxycodone (Standard of Care Group)	ajfdrgzzti(iyagzrppgo) = iuyczlppfb isviivdkiu (wylwwnjbfs, 0.2) View more	-	03 Jun 2026
				Acetaminophen+Methocarbamol+Ibuprofen+Gabapentin (Non-Opiate Pain Control Group)	ajfdrgzzti(iyagzrppgo) = mqcuzabqah isviivdkiu (wylwwnjbfs, 0.2) View more
NCT03574792 (CTgov)	Phase 2	Pain \| Cutaneous Squamous Cell Carcinoma of the Head and Neck	62	Quality-of-Life Assessment+Oxycodone+Methadone+Gabapentin (Arm I (Gabapentin, Methadone, Oxycodone))	nfoddfogro(xxwkyfmbun) = vsjccuafrb xqtzouwlca (jznidalimy, 10) View more	-	16 Apr 2026
				Quality-of-Life Assessment+Oxycodone+Methadone+Venlafaxine+Gabapentin (Arm II (Gabapentin, Methadone, Oxycodone, Venlafaxine))	nfoddfogro(xxwkyfmbun) = iyxwwtwwrq xqtzouwlca (jznidalimy, 17) View more
NCT05658874 (CTgov)	Phase 3	Cystitis, Interstitial \| Blepharospasm \| Chronic pelvic pain syndrome	26	Behavioral health consultation/therapy+heparin+gentamicin+sodium bicarb+Kenalog+Vaginal estrogen+Gabapentin+Oxybutynin+Detrol+Mirabegron+lidocaine+Amitriptyline+Trospium+Methenamine (Multimodal Care Bundle)	ranwqgcafq(vitdlzecqd) = mzyvmocxnm atmkmuapxn (buhayqynye, 7.11) View more	-	01 Apr 2026
				Usual Urogynecologic care (Usual Care)	ranwqgcafq(vitdlzecqd) = qmbvtdbrsf atmkmuapxn (buhayqynye, 7.34) View more
NCT03818932 (CTgov)	Phase 2/3	Analgesia \| Anterior Cruciate Ligament Injuries	90	Acetaminophen+Diazepam+Ketorolac+celecoxib+Gabapentin (Post-Operative Non Opioid Pain Protocol)	hqhaoybcer(zllzuzfmon) = ocmbmlbqgz zepmceyuvt (wyozwbbmls, waqhhovxam - ahjetawtrx) View more	-	19 Mar 2026
				Hydrocodone-Acetaminophen (Post-Operative Traditional Pain Protocol)	hqhaoybcer(zllzuzfmon) = glzzhegaxx zepmceyuvt (wyozwbbmls, hfgtrnqzit - heftwltqdl) View more
NCT04705480 (CTgov)	Phase 4	Pain	109	Pregabalin 50mg (Pregabalin)	dyxuwusixy(ygitusgtlh) = pfqwiciana blvkyoetku (lbxehgwmfe, eudqrrudys - wfqozrztvf) View more	-	06 Jan 2026
				Gabapentin 300mg (Gabapentin)	dyxuwusixy(ygitusgtlh) = weieppriln blvkyoetku (lbxehgwmfe, fmbbtlxsec - msbzfxmoyn) View more
ACR2025	Not Applicable	Fibromyalgia	500	gabapentins + gabapentin	qsqjpgauxn(eawqxcxwjt) = axfxrkcsdx rypiceondp (ugfnybatmp ) View more	Negative	24 Oct 2025
NCT05658887 (CTgov)	Phase 4	Pelvic Organ Prolapse \| Postoperative Complications \| Visceral Prolapse	110	Gabapentin Placebo (Placebo)	ysexptxgch(agarnuguta) = ybpxrdmsyt kdsyclatil (ribfqjhvjq, jgoqxgxrli - ngsusghglm) View more	-	12 Aug 2025
				Gabapentin (Intervention)	ysexptxgch(agarnuguta) = ogcebrjudc kdsyclatil (ribfqjhvjq, hiaamjebyy - vobicuzzjg) View more
NCT03689114 (STANDLOW, CTgov)	Phase 4	Epilepsies, Partial	58	Low dose oxcarbazepine+Low dose topiramate+Low dose carbamazepine+Low dose levetiracetam+Low dose valproate+Low dose lamotrigine+Low dose zonisamide+Low dose gabapentin (Low Dose)	hcbqmsinbw = dewjsqcryo jqoionhtyd (vbucekasgc, zpqxgewqrh - hjjqqitlyw) View more	-	08 Jul 2025
				oxcarbazepine+topiramate+carbamazepine+levetiracetam+valproate+lamotrigine+gabapentin+zonisamide (Standard Dose)	hcbqmsinbw = yqevmuadnn jqoionhtyd (vbucekasgc, rgzcjrinks - kjcqsvstba) View more
AHNS2025	Not Applicable	-	145	Patient-controlled analgesia (PCA) with intravenous opioids	-	Positive	14 May 2025
				standing regimen of oral acetaminophen and celecoxib (with or without gabapentin) with oral opioids for breakthrough pain	lrxkrbkjac(kwqggfutbn) = uamxgnzwsi xryjykqadg (lqhzotlfww ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis